Home
Search
Study Topics
Glossary
|
Study 15 of 5951 for search of: | United States, North Carolina |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00051103 |
The purpose of this study is to determine the efficacy of an oral investigational drug for the treatment of metastatic breast cancer tumors that are known to overexpress HER2/neu.
Condition | Intervention | Phase |
---|---|---|
Metastatic Breast Cancer |
Drug: Investigational Cancer Drug |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: (The patient must meet the following criteria in order to be eligible for this study.)
Exclusion Criteria: (The patient cannot meet any of the following criteria in order to be eligible for this study.)
Study ID Numbers: | EGF 20002 |
Study First Received: | January 3, 2003 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00051103 |
Health Authority: | United States: Food and Drug Administration |
Refractory |
Skin Diseases Trastuzumab Breast Neoplasms Breast Diseases |
Neoplasms Neoplasms by Site |